The Tissue Procurement Shared Resource (TPSR) at the Ohio State University (OSU) was established on the initial award by the NCI for the OSU Comprehensive Cancer Center (CCC). In 1987, the TPSR was awarded an NCI grant for the Cooperative Human Tissue Network (CHTN) and in 1995, was again awarded an NCI grant for the AIDS Malignancy Bank (AMB). Together, these three grants comprise the TPSR in the Department of Pathology and indirectly support each other through consolidation of effort. The TPSR prospectively procures remnant human specimens for CCC research investigators. All applications require Institutional Review Board (IRB) approval and then specimens are provided, determined by the members' need and subject to availability. Procurement of tissue specimens from OSU and Grant Hospitals are prioritized for CCC investigators. Research specimens distributed to investigators are accompanied by donor information including age, gender and race and pathologist's gross and microscopic diagnosis. TPSR personnel gather additional medical information such as smoking history, radiation, chemotherapy, and other pertinent facts regarding the patient through medical records. All specimens are uniquely coded to assure patient confidentiality. TPSR consistently procures and distributes approximately 3,000 specimens per year from OSU and Grant Hospitals to more than 35 CCC members. The TPSR has been invaluable to CCC investigators' research, measured by a consistent number of original articles published ear year in peer-reviewed journals. Moreover, in this request for renewal, the TPSR is adding laser capture microdissection (LCM) technology for CC investigators use to enhance the value of tissue specimens used in research applications.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-26
Application #
6430839
Study Section
Project Start
2001-03-07
Project End
2001-11-30
Budget Start
Budget End
Support Year
26
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
098987217
City
Columbus
State
OH
Country
United States
Zip Code
43210
Nakashima, Hiroshi; Alayo, Quazim A; Penaloza-MacMaster, Pablo et al. (2018) Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells. Sci Rep 8:208
Coss, Christopher C; Clinton, Steven K; Phelps, Mitch A (2018) Cachectic Cancer Patients: Immune to Checkpoint Inhibitor Therapy? Clin Cancer Res 24:5787-5789
Rogers, Kerry A; Huang, Ying; Ruppert, Amy S et al. (2018) Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia. Blood 132:1568-1572
Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies. Leukemia 32:1338-1348
Burton, Jenna H; Mazcko, Christina; LeBlanc, Amy et al. (2018) NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma. Clin Cancer Res 24:5830-5840
Salzer, Wanda L; Burke, Michael J; Devidas, Meenakshi et al. (2018) Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131. Cancer 124:1150-1159
Yu, Peter Y; Lopez, Gonzalo; Braggio, Danielle et al. (2018) miR-133a function in the pathogenesis of dedifferentiated liposarcoma. Cancer Cell Int 18:89
Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome. Leukemia 32:2536-2545
Sprague, Leslee; Lee, Joel M; Hutzen, Brian J et al. (2018) High Mobility Group Box 1 Influences HSV1716 Spread and Acts as an Adjuvant to Chemotherapy. Viruses 10:
Koster, Roelof; Panagiotou, Orestis A; Wheeler, William A et al. (2018) Genome-wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients. Int J Cancer 142:1594-1601

Showing the most recent 10 out of 2602 publications